TLDR
- JNJ hit an all-time high of $275.48, with a market cap of $661 billion
- The stock is up 53% over the past year, with a total return of 56.29%
- Q2 sales rose 6.6% to $25.31 billion; adjusted EPS came in at $2.90
- Management raised its 2026 revenue outlook to approximately $101.1 billion
- Multiple analysts raised price targets, with Guggenheim setting a $287 target
Johnson & Johnson hit a new all-time high of $275.48 on Tuesday, August 19, pushing its market cap to $661 billion. The stock has gained 53% over the past year.
The move follows a strong second quarter. Q2 sales rose 6.6% to $25.31 billion, and adjusted earnings came in at $2.90 per share. Those numbers beat expectations and gave management the confidence to raise its 2026 outlook.
JNJ now targets roughly $101.1 billion in full-year revenue and $11.68 in adjusted earnings per share at the midpoint. That puts it close to a milestone few healthcare companies ever reach: $100 billion in annual sales.
The rally was partly driven by a broader rotation. As the Nasdaq faced selling pressure Tuesday, investors moved into defensive names. JNJ was one of the clearest beneficiaries, jumping around 3% to $270.19 before pushing to fresh highs the following day.
TREMFYA revenue came in roughly $400 million above projections. CAPLYTA and SPRAVATO also beat expectations, adding fuel to the analyst upgrades that followed the earnings report.
Analyst Upgrades Follow Strong Results
Guggenheim raised its price target to $287 from $270 and kept its Buy rating. The firm cited a site visit with senior management as part of its updated view.
Raymond James lifted its target to $280 from $265. The recent FDA approval of J&J’s Ottava robotic surgery platform and its limited launch factored into that call.
Freedom Capital went a step further, upgrading the stock from Hold to Buy and setting a $280 target. The firm pointed to Q2 results that topped both consensus and its own estimates.
JNJ has also raised its dividend for 55 consecutive years. That track record keeps income-focused investors in the stock, even at current valuations.
Valuation Is a Key Question
The stock is not cheap. JNJ trades at a price-to-earnings ratio of 31.37. InvestingPro flags the stock as overvalued relative to its Fair Value estimate.
The GF Value chart puts JNJ’s estimated fair value at $192.38, meaning the stock is trading roughly 41% above that figure. The market is pricing in strong execution from its pharma pipeline and medical device portfolio.
Elsewhere in healthcare, Medtronic got attention from Piper Sandler, which kept a Neutral rating and a $85 price target. A survey of 26 physicians suggested Medtronic is expected to lead in PFA catheters and mapping through 2028.
JNJ’s stock was trading at $275.48 as of August 19, a new all-time high.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
